284 results on '"Sommerburg O"'
Search Results
2. Chronische Rhinosinusitis bei Menschen mit zystischer Fibrose – eine aktuelle Übersicht aus der Perspektive der Hals‑, Nasen‑, Ohrenheilkunde
3. WS11.03 Early cystic fibrosis lung disease in the TRACK-CF cohort: what longitudinal multiple-breath washout and chest magnetic resonance imaging teach us
4. Chronic rhinosinusitis in people with cystic fibrosis—an up-to-date review from the perspective of otorhinolaryngology
5. Magnetresonanztomographie der Lunge bei Mukoviszidose
6. Computertomographie der Lunge bei Mukoviszidose
7. 121 Longitudinal MRI of morphological and perfusion abnormalities in children with cystic fibrosis from infancy to end of adolescence
8. 139 Comprehension of early cystic fibrosis lung disease or howto TRACK-CF
9. 111 Long-term effects of lumacaftor-ivacaftor on chronic rhinosinusitis in children with cystic fibrosis detected with MRI
10. 110 Elexacaftor-tezacaftor-ivacaftor improves bronchial artery dilatation detected using MRI in people with cystic fibrosis
11. Niemann-Pick Type C-2 Disease: Identification by Analysis of Plasma Cholestane-3β,5α,6β-Triol and Further Insight into the Clinical Phenotype
12. Diagnostik und Management der Choanalatresie
13. Neugeborenenscreening 2020: Perspektiven der Krankheitsfrüherkennung
14. Das Mukoviszidosescreening wird in Deutschland eingeführt: Was müssen die Pädiater in der Praxis wissen?
15. 184 Effects of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles
16. Comparison of the lung clearance index in preschool children with primary ciliary dyskinesia and cystic fibrosis
17. Comparison of the Lung Clearance Index in preschool children with Primary Ciliary Dyskinesia and Cystic Fibrosis
18. WS17.02 Long-term efficacy of lumacaftor/ivacaftor (LUM/IVA) in children aged 2 through 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation (F/F): a phase 2, open-label extension study
19. ePS5.09 Comparison of the Lung Clearance Index in preschool children with primary ciliary dyskinesia and cystic fibrosis
20. WS06.04 Effects of elexacaftor/tezacaftor/ivacaftor therapy on CFTR function in patients with cystic fibrosis and 1 or 2 F508del alleles
21. Lungenerkrankungen im Kindesalter
22. 147 Early cystic fibrosis lung disease progression by multiple-breath washout and chest MRI.
23. Stridor, rezidivierende Bronchitiden und Gedeihstörung
24. WS06.1 Defining key outcomes to evaluate performance of newborn screening programmes for cystic fibrosis
25. WS12.1 An exploratory study to determine the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression in children 2 through 5 years of age with cystic fibrosis homozygous for F508del-CFTR (F/F)
26. Algorithm for early diagnosis in nontuberculous mycobacterial lymphadenitis
27. P242 Therapy with lumacaftor/ivacaftor (LUM/IVA) in paediatric patients with liver cirrhosis
28. β-Carotene breakdown products enhance genotoxic effects of oxidative stress in primary rat hepatocytes
29. Effect of carotenoid oxidation products on neutrophil viability and function
30. Cyto- and genotoxic potential of β-carotene and cleavage products under oxidative stress
31. Cytotoxic and genotoxic effects of β-carotene breakdown products on primary rat hepatocytes
32. CYTOTOXIC AND GENOTOXIC EFFECTS DUE TO BETA-CAROTENE CLEAVAGE PRODUCTS POSSIBLY FORMED IN INFLAMED LUNG TISSUE: S24-129
33. THE EVALUATION OF FREE RADICAL METABOLISM ARGUES FOR A COMPLETE CORRECTION OF RENAL ANEMIA BY ERYTHROPOIETIN
34. Improved antioxidative protection in winter swimmers
35. P262 Effects of lumacaftor/ivacaftor therapy on lung disease detected by magnetic resonance imaging in F508del homozygous patients with cystic fibrosis
36. P257 Ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function is evaluated in a patient with 3849 + 10kbC > T mutation
37. P142 Effects of short-term lumacaftor/ivacaftor therapyon lung microbiome in F508del homozygous patients with cystic fibrosis
38. Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: patient-reported outcomes in a Phase 3, randomised, controlled trial (EVOLVE)
39. Esophagael Lung – eine seltene Diagnose im Kindesalter
40. WS14.3 Randomised, double-blind, controlled pilot study on safety and efficacy of hypertonic saline as preventive inhalation therapy in infants with CF (PRESIS)
41. Einführung des Neugeborenen-Screenings auf Mukoviszidose in Deutschland
42. UPDATED SURVEY OF NEWBORN SCREENING FOR CYSTIC FIBROSIS IN EUROPE
43. Neugeborenenscreening 2020
44. WS12.2 Increased fracture rate in relation to macroscopic bone architecture in young patients with cystic fibrosis
45. Imaging of Cystic Fibrosis Lung Disease and Clinical Interpretation
46. Disturbed accumulation and abnormal distribution of macular pigment in retinal disorders
47. Thorakale Aktinomykose als seltene Ursache eines hämorrhagischen Perikardergusses
48. Intestinal Current Measurements Detect Activation of Mutant CFTR in Cystic Fibrosis Patients with the G551D Mutation Treated with Ivacaftor
49. Combining IRT/PAP+SN with DNA analysis for the best CF newborn screening strategy for Germany
50. 146 Sinonasal inhalation of isotonic vs. hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis – results of a multicentre, double-blind, controlled prospective trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.